Astrazeneca plc is investing heavily in China, signing two R&D deals, worth up to about $8 billion in up-front payments and ...

With over 35 years in China, Vantive has operated three manufacturing facilities in Suzhou, Jiangsu province, Guangzhou, ...

The largest of the collaborations is a potentially more than $4.68 billion partnership with Shanghai-based Harbour BioMed to discover and develop next-generation multi-specific antibodies for ...